You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company develops microarray-based pathogen detection products based on a proprietary genotyping technology.
The latest round, led by Northpond Ventures, brings the total amount raised by the
company to date to $76 million.
It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.
The Beijing-based firm said it will use the funding for research and development, to obtain additional intellectual property, and to pursue its strategic goals.
The company plans to use the new funding to grow its suite of genomics applications to more than 50 in 2018.
The financing will support business expansion, continued technology development, and expenses related to a planned listing at the end of the year.
The Swedish molecular diagnostics firm will use the proceeds, in part, to fund the planned launch of its Immray PanCan-d assay for detecting pancreatic cancer.
The company is developing a platform for synthesizing biomedical knowledge from scientific, regulatory, and commercial literature.
The firm said it will use the funds to commercialize Colvera, its liquid biopsy test for earlier detection of recurrent colorectal cancer.
The company entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.
The US has sent its formal notice of withdrawal from the World Health Organization, according to the Wall Street Journal.
Science reports that a draft spending bill would increase the US National Institutes of Health budget by 13 percent.
The Harvard Crimson reports that Harvard and MIT are suing the Department of Homeland Security and ICE over the new international student visa policy.
In Nucleic Acids Research this week: algorithm to determine molecular sequence types and other microbial features, computational method to uncover R-loop structures, and more.